Ocugen, Inc.

Equities

OCGN

US67577C1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 30/04/2024 am IST			5-day change	1st Jan Change
1.39 ^USD	+8.59%		+12.10%	+141.74%

22/04	Chardan Adjusts Price Target on Ocugen to $5 From $4, Maintains Buy Rating	MT
22/04	Chardan Raises Price Target on Ocugen to $5 From $4, Keeps Buy Rating	MT

Ocugen, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021

February 25, 2022 at 06:11 pm IST

Ocugen, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2021. For the fourth quarter, the company reported net loss was USD 14.58 million compared to USD 3.79 million a year ago. Basic loss per share from continuing operations was USD 0.07 compared to USD 0.02 a year ago.
For the full year, net loss was USD 58.37 million compared to USD 21.82 million a year ago. Basic loss per share from continuing operations was USD 0.3 compared to USD 0.31 a year ago.

Latest news about Ocugen, Inc.

Chardan Adjusts Price Target on Ocugen to $5 From $4, Maintains Buy Rating	22/04	MT
Chardan Raises Price Target on Ocugen to $5 From $4, Keeps Buy Rating	22/04	MT
Ocugen Completes Dosing in Trial of Gene Therapy for Macular Degeneration	19/04	MT
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy	19/04	CI
Ocugen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	17/04	CI
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for Ocu400?Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication	10/04	CI
Ocugen Gets FDA Clearance for IND Amendment for OCU400	08/04	DJ
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial	08/04	CI
Sector Update: Health Care Stocks Rise Late Afternoon	06/04	MT
Sector Update: Health Care Stocks Rise Friday Afternoon	05/04	MT
Ocugen Says Data, Safety Monitoring Board Issues 'Positive' Review of Eye Disease Treatment -- Shares Rise	05/04	MT
Ocugen, Inc. Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410--A Modifier Gene Therapy-- in Phase 1/2 Armada Study for Geographic Atrophy	05/04	CI
Sector Update: Health Care Stocks Slipping in Afternoon Trading	02/04	MT
Ocugen to Restate Financial Statements; Shares Tumble	02/04	MT
Transcript : Ocugen, Inc., Q4 2023 Earnings Call, Apr 02, 2024	02/04
Ocugen Provides Business Update	02/04	CI
North American Morning Briefing : Stocks Seen -2-	02/04	DJ
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410st?A Modifier Gene Therapy?In Gardian Study for Stargardt Disease	02/04	CI
North American Morning Briefing : Markets Steady -2-	26/03	DJ
Sector Update: Health Care Stocks Steady Premarket Monday	25/03	MT
Sector Update: Health Care Stocks Ease Late Afternoon	23/03	MT
Ocugen Stock Rallies After Appeals Court Dismisses Allegations of Misleading Shareholders	23/03	MT
Ocugen, Inc. Announces Ramesh Kumar Will Not Stand for Re-Election as Director	21/03	CI
North American Morning Briefing : Stock Futures -2-	19/03	DJ
Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer	18/03	CI

Chart Ocugen, Inc.

Duration

Period

More charts

Company Profile

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.

Sector

Biotechnology & Medical Research

Calendar

03/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.39 USD

Average target price

6.667 USD

Spread / Average Target

+379.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OCUGEN, INC.	+141.74%	358M
IQVIA HOLDINGS INC.	+1.77%	42.86B
LONZA GROUP AG	+47.70%	41.36B
MODERNA, INC.	+12.24%	42.74B
CELLTRION, INC.	-8.83%	27.68B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.63B
MEDPACE HOLDINGS, INC.	+30.56%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.92B
UNITED THERAPEUTICS CORPORATION	+8.35%	11.21B

Other Biotechnology & Medical Research